Famotidine in the management of gastro-oesophageal reflux.

dc.contributor.author	Okoth, FA
dc.contributor.author	Lule, GN
dc.contributor.author	Ogutu, EO
dc.contributor.author	Pilczer, S
dc.contributor.author	Dubois, C.
dc.date.accessioned	2013-04-26T10:23:19Z
dc.date.available	2013-04-26T10:23:19Z
dc.date.issued	1994
dc.identifier.citation	East Afr Med J. 1994 Jan;71(1):44-8.	en
dc.identifier.uri	http://hinari-gw.who.int/whalecomwww.ncbi.nlm.nih.gov/whalecom0/pubmed/8055765
dc.identifier.uri	http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/17042
dc.description.abstract	Famotidine has been used for the treatment of peptic ulcers and Zollinger Ellison syndrome and is also useful in reflux and erosive oesophagitis. To evaluate the effects of Famotidine 20 mg given twice daily in the symptomatic relief of gastro-oesophageal reflux disease with normal oesophagus or mild endoscopic oesophagitis, patients were followed over a period of six weeks. 70% of the patients had complete day-time heartburn relief during the study and 75% had complete night-time heartburn relief during the study. Famotidine was found to be safe and there were no serious clinical or laboratory adverse experiences.	en
dc.language.iso	en	en
dc.title	Famotidine in the management of gastro-oesophageal reflux.	en
dc.type	Article	en